Lucid Diagnostics Inc.

NASDAQ:LUCD

Medical - Devices

Healthcare
$0.41 +3.80%

+$0.04 today

Market cap
$79.38M
Beta
1.08
P/E (TTM)
-2.3
EPS (TTM)
-$0.44
52W Low $0.90High $1.63

Volume 2.70M

Average 0.84M

LUCD Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Lucid Diagnostics Inc.NASDAQ: LUCD

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $13.91M (cash outflow) fell 48.3% year over year, behind the +43056.2% change in trailing-twelve-month net income. Sequentially, it fell 99.9% from the prior quarter. Over 3 fiscal years it compounded at +1.1% a year.

Context

  • Net income amounted to 1232.7% of revenue in FY2025, up 185.1 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$28.82M (-50.3%) for the fiscal year ending Dec 2026, a slowdown from the +27.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.91M-99.9% QoQ
Last fiscal yearDec 2025
-$58.01M+27.4% YoY
LTMMar 2026
-$26.68B+43056.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-48.3%+143.8%+192.1 pp
1 year+27.4%-50.3%-77.7 pp
3-year CAGR+1.1%-34.9%-36.0 pp
5-year CAGR-34.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(58.01M) USD
Year-over-year change
-27.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How LUCD compares with its peers on the latest reported figures

  • LUCD's LTM Mar 2026 net income of $26.68B is the largest of the 10 companies compared; the peer median is $70.49M.
  • Its year-over-year change of +43056.2% is the highest of 10, against a peer median of +11.8%.
  • Net income amounts to 519699.0% of revenue for LUCD, versus a peer median of 468.7%.
LUCD Competitors Peer median
Net Income for LUCD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$26.68B +43056.2%+1.1%519699.0%
SCLXScilex Holding CompanyLTM Mar 2026$380.63M +410.8%+148.5%1124.1%
STSSSkyAI, Inc.LTM Mar 2026$358.5M +5514.8%+287.7%90325.9%
IRDOpus Genetics, Inc.LTM Mar 2026$106.93M +82.4%—892.4%
AVRAnteris Technologies Global Corp.LTM Mar 2026$88.03M +7.6%+45.5%4756.0%
SEERSeer, Inc.LTM Mar 2026$70.49M -17.9%-7.5%468.7%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$50.14M +11.8%-8.1%145.8%
OWLTOwlet, Inc.LTM Mar 2026$46.04M +260.1%-21.4%43.0%
RCELAVITA Medical, Inc.LTM Mar 2026$45.34M -20.5%+22.1%62.7%
APYXApyx Medical CorporationLTM Mar 2026$9.05M -55.1%-21.9%16.2%
Peer median (excluding LUCD) $70.49M+11.8%+7.3%468.7%

Competitors are the stored peer set for LUCD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.08M)(56.17M)(52.67M)(45.53M)(58.01M)
Depreciation & Amortization4K1.94M2.5M1.17M872K
Deferred Income Tax00000
Stock-Based Compensation9.6M14.99M6.82M4.53M4.49M
Change in Working Capital807K8.91M5.68M(4.43M)(2.81M)
Accounts Receivables(200K)183K(28K)0(601K)
Inventory00000
Accounts Payables(665K)(445K)89K96K(270K)
Other Working Capital1.67M9.17M5.61M(4.53M)(1.94M)
Other Non-Cash Items9.6M653K4.85M119K8.97M
Operating Cash Flow(17.67M)(29.69M)(32.82M)(44.14M)(46.49M)
Capital Expenditures(862K)(908K)(221K)(646K)(197K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(3.2M)0(350K)0
Investing Cash Flow(862K)(4.11M)(221K)(646K)(197K)
Debt Repayment0010M18M360K
Common Stock Issued77.74M1.81M284K451K58.67M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(5.66M)804K551K451K0
Financing Cash Flow72.08M2.61M29.46M48.25M59.03M
Effect of Forex Changes(255)0000
Net Change in Cash53.54M(31.18M)(3.58M)3.46M12.35M
Free Cash Flow(18.53M)(30.59M)(33.04M)(44.79M)(46.49M)

Lucid Diagnostics Inc.

NASDAQ:LUCD

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.